Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07590986

Enrollment

150

Registered

2026-05-15

Start date

2026-05-01

Completion date

2037-01-01

Last updated

2026-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential Thrombocythemia (ET), Myeloproliferative Neoplasm (MPN), Polycytemia Vera, Primary Myelofibrosis (PMF)

Brief summary

The goal of this observational study is to learn how the immune system responds to myeloproliferative neoplasms (MPN) in adults with known or suspected MPN. Researchers also want to identify immune cells that could help develop future immune-based treatments for MPN. The main questions it aims to answer are: * Are there T cells in the bone marrow that can recognize MPN cells? * Which targets (antigens) on MPN cells are recognized by these immune cells? * Can researchers identify T cell receptors (TCRs) that may be used in future TCR-based therapies? Researchers will study samples from adults with polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), post-PMF, or unclassifiable MPN. Samples from healthy donors without blood disorders will also be included for comparison. By providing blood and bone marrow samples, participants will: * Allow researchers to study immune cells and genetic material from these samples * Allow researchers to perform laboratory tests to study how immune cells recognize MPN cells Researchers will use laboratory methods such as genetic sequencing, cell analysis, and cell culture experiments to better understand immune responses in MPN. Participants will not receive direct medical benefit from this study. The results may help researchers better understand MPN and support the future development of immune-based therapies.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Patients previously diagnosed or suspected of having PV, ET, pre-PMF, overt PMF, or an unclassifiable MPN. * Patients not previously diagnosed with a haematological disease as controls

Exclusion criteria

* Patients with any other hematological malignancy.

Design outcomes

Primary

Measure	Time frame
Identification of MPN-specific CD8+ T cell clonotypes and corresponding tumor antigens	Throughout the whole study, approximately during 10 years

Countries

Belgium

Contacts

CONTACTSophie Lucas

sophie.lucas@uclouvain.be0032 (0)2 436 23 00

Outcome results